Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Background</h3><p>Epidermolysis bullosa (EB) is a heterogeneous group of rare and incurable genetic disorders characterized by fragility of the skin and mucosae, resulting in blisters and erosions. Several epidemiological studies in other populations have been carried out, reporting varying and sometimes inconclusive figures, highlighting the need for standardized epidemiological analyses in well‐characterized cohorts.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Objectives</h3><p>To evaluate the epidemiological data on EB in the Netherlands, extracted from the molecularly well‐characterized cohort in the Dutch EB Registry.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Methods</h3><p>In this observational study all EB‐patients that were based in the Netherlands and captured in the Dutch EB Registry between 1988 and 2018 were included. The epidemiological outcomes were based on complete diagnostic data (clinical features, immunofluorescence, electron microscopy, and mutation analysis), with longitudinal follow‐up.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Results</h3><p>A total of 464 EB‐patients (287 families) were included. The incidence and point‐prevalence of EB in the Netherlands were 41.3 per million live births and 22.4 per million population, respectively. EB Simplex (EBS), Junctional EB (JEB), Dystrophic EB (DEB) and Kindler EB were diagnosed in 45.7%, 18.8%, 34.7% and 0.9% of the EB‐patients, respectively, with an incidence and point‐prevalence of 17.5 and 11.9 (EBS), 9.3 and 2.1 (JEB), 14.1 and 8.3 (DEB), 0.5 and 0.2 (Kindler EB). In 90.5% of the EB‐patients the diagnosis was genetically confirmed. During the investigated time period 73 EB‐patients died, 72.6% of whom as a direct consequence of their EB.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Conclusion</h3><p>The epidemiological outcomes of EB in the Netherlands are high, attributed to a high detection rate in a well‐organized setup, indicating that EB might be more common than previously assumed. These epidemiological data help to understand the extensive need for (specialized) medical care of EB‐patients and is invaluable for the design and execution of therapeutic trials. This study emphasizes the importance of thorough reporting systems and registries worldwide.</p></section>

Genetic Implications and Management of Epidermolysis Bullosa in the Saudi Arabian Population

Clinical and molecular features in a cohort of Middle Eastern patients with epidermolysis bullosa

Advances in Treatments for Epidermolysis Bullosa (EB): Emphasis on Stem Cell-Based Therapy

Epidermolysis Bullosa: Two rare case reports of COL7A1 and EBS-GEN SEV KRT14 variants with review of literature

Inpatient Management of Epidermolysis Bullosa: Consensus-Based Hands-On Instructions for Neonates and Post-Neonates

Clinical practice guidelines for laboratory diagnosis of epidermolysis bullosa

Skin Microbial Composition and Genetic Mutation Analysis in Precision Medicine for Epidermolysis Bullosa

Investigational Treatments for Epidermolysis Bullosa

Molecular profiling of an Indian EB cohort – a single centre experience

Novel insights into the epidemiology of epidermolysis bullosa (EB) from the Dutch EB Registry: EB more common than previously assumed?

Management of Skin Lesions in Patients with Epidermolysis Bullosa by Topical Treatment: Systematic Review and Meta-Analysis

Epidermolysis bullosa: Advances in research and treatment

Epidermolysis Bullosa—A Kindler Syndrome Case Report and Short Literature Review

Gene-edited cells: novel allogeneic gene/cell therapy for epidermolysis bullosa

Hereditary epidermolysis bullosa: clinical-epidemiological profile of 278 patients at a tertiary hospital in São Paulo, Brazil

Molecular pathology of the basement membrane zone in heritable blistering diseases:: The paradigm of epidermolysis bullosa

A Catheter Securement Strategy for Patients with Epidermolysis Bullosa

The Clinical and Mutational Spectrum of Bardet–Biedl Syndrome in Saudi Arabia

Genotype and Phenotype Correlations in 441 Patients with Epidermolysis Bullosa from China

Evolution of genome diagnostics in epidermolysis bullosa: Unveiling the power of next‐generation sequencing

Familial Screening for the Prevention of Rare Diseases: A Focus on Lipodystrophy in Southern Saudi Arabia